LOCKED CV Transforum Fall’18 – Role of SGLT2/GLP1 RA in a Preventative Cardiologist’s Practice - Dr. Mikhail Kosiborod

Posted on: October 13, 2018


Dr. Kosiborod will discuss the fundamental paradigm shift in T2D management. He will review several classes of glucose-lowering medications that improve CV outcomes and emerging data on the shift of focus from HbA1c alone to comprehensive CV risk reduction. Finally, he will share why all of this points to the need for cardiologists to take a more active role in T2D management.

This site uses cookies to improve your experience.

By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.